title: Vitamin D receptor gene polymorphisms affect secondary hyperparathyroidism in hemodialyzed patients.
abstract: Adynamic bone disease unrelated to aluminum deposition, with low parathyroid hormone (PTH) levels, has increased in patients with end-stage renal failure. Some patients present with severe secondary hyperparathyroidism despite calcitriol administration and phosphate restriction. Because therapeutic and environmental factors are now similar among hemodialyzed patients, the variable incidence of secondary hyperparathyroidism may be caused by genetic heterogeneity. To examine this possibility, we analyzed restriction fragment length polymorphisms of the vitamin D receptor (VDR) gene in 877 Japanese hemodialysis patients. VDR allelic polymorphism was determined by the method of Morrison et al. Polymerase chain reaction (PCR) amplification and a BsmI endonuclease restriction site at the 5' end of the VDR gene defined BB (absence of restriction site on both alleles), Bb (heterozygous), or bb (restriction site on both alleles). The mean serum PTH level was lower in BB patients (86 +/- 102 pg/mL) than in bb patients (148 +/- 217 pg/mL; P < 0.05). The serum osteocalcin level was also lower in BB than in bb patients (P < 0.05). If results were re-analyzed excluding patients with a history of dialysis exceeding 10 years or those with non-insulin-dependent diabetes mellitus (NIDDM) or who had undergone parathyroidectomy, the differences in serum PTH levels were greater. However, there was no significant difference in serum PTH levels among the VDR genotypes, only for patients with NIDDM. The present study shows that patients with the b allele for the VDR gene have more severe secondary hyperparathyroidism than patients without the b allele. However, NIDDM or a long history of hemodialysis has a stronger power to influence PTH secretion.
authors.affiliation: Fourth Department of Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Nagaba
authors.forename: M
authors.initials: M
authors.lastname: Heishi
authors.forename: H
authors.initials: H
authors.lastname: Tazawa
authors.forename: Y
authors.initials: Y
authors.lastname: Tsukamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kobayashi
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics; D005260:Female; D006580:Genetic Carrier Screening; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D016105:Parathyroidectomy; D011110:Polymorphism, Genetic / Q000235:genetics*; D012150:Polymorphism, Restriction Fragment Length; D018167:Receptors, Calcitriol / Q000235:genetics*; D006435:Renal Dialysis; D012307:Risk Factors
chemical_list: D010281:Parathyroid Hormone; D018167:Receptors, Calcitriol